{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:57:53Z","timestamp":1770292673927,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.medcli.2025.106951","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:53:14Z","timestamp":1747309994000},"page":"106951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["F\u00e1rmacos con acci\u00f3n GLP-1 en el tratamiento de la obesidad: efectos sobre las variables cardiometab\u00f3licas y la enfermedad cardiovascular"],"prefix":"10.1016","volume":"165","author":[{"given":"Helena","family":"Sard\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idoia","family":"Genua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inka","family":"Mi\u00f1ambres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.106951_bib0305","series-title":"Obesity Atlas 2024","year":"2024"},{"key":"10.1016\/j.medcli.2025.106951_bib0310","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0315","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/nu16162781","article-title":"Update on obesity and cardiovascular risk: From pathophysiology to clinical management","volume":"16","author":"Gallo","year":"2024","journal-title":"Nutrients."},{"key":"10.1016\/j.medcli.2025.106951_bib0320","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","article-title":"Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study","volume":"67","author":"Hubert","year":"1983","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106951_bib0325","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/eurjpc\/zwae279","article-title":"Obesity and cardiovascular disease: An ESC clinical consensus statement","volume":"32","author":"Koskinas","year":"2025","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0330","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/archinte.167.16.1720","article-title":"Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: A meta-analysis of 21 cohort studies including more than 300 000 persons","volume":"167","author":"Bogers","year":"2007","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0335","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106951_bib0340","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(11)60105-0","article-title":"Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies","volume":"377","author":"Wormser","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106951_bib0350","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/eurheartj\/ehn573","article-title":"Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study","volume":"30","author":"Mahabadi","year":"2009","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2025.106951_bib0355","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jcmg.2016.10.024","article-title":"Pericardial, but not hepatic, fat by CT is associated with CV outcomes and structure: The Multi-Ethnic Study of Atherosclerosis","volume":"10","author":"Shah","year":"2017","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.medcli.2025.106951_bib0360","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","article-title":"Obesity and the risk of cardiometabolic diseases","volume":"20","author":"Valenzuela","year":"2023","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0365","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0370","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial","volume":"30","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2025.106951_bib0375","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2025.106951_bib0380","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sj\u00f6str\u00f6m","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0385","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sj\u00f6str\u00f6m","year":"2007","journal-title":"N Engl J Med."},{"issue":"Suppl 3","key":"10.1016\/j.medcli.2025.106951_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract."},{"key":"10.1016\/j.medcli.2025.106951_bib0395","doi-asserted-by":"crossref","first-page":"102953","DOI":"10.1016\/j.aprim.2024.102953","article-title":"Efectos cardiometab\u00f3licos de la p\u00e9rdida de peso","volume":"56","author":"Genua","year":"2024","journal-title":"Aten Primaria."},{"key":"10.1016\/j.medcli.2025.106951_bib0400","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes (Lond)."},{"key":"10.1016\/j.medcli.2025.106951_bib0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0415","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0420","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0425","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0430","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2025.106951_bib0435","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2 4mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0440","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet."},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2025.106951_bib0445","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J Endocr Soc."},{"key":"10.1016\/j.medcli.2025.106951_bib0450","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2025.106951_bib0455","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2025.106951_bib0460","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.medcli.2025.106951_bib0465","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013Associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0470","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106951_bib0475","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0480","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2 4mg versus placebo in people with obesity and prediabetes (STEP 10): A randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2025.106951_bib0485","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2025.106951_bib0490","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0495","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2025.106951_bib0500","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/nu11071667","article-title":"Weight loss and hypertension in obese subjects","volume":"11","author":"Fantin","year":"2019","journal-title":"Nutrients."},{"key":"10.1016\/j.medcli.2025.106951_bib0505","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: A meta-analysis of randomized controlled trials","volume":"24","author":"De Oliveira Almeida","year":"2024","journal-title":"Am J Cardiovasc Drugs."},{"key":"10.1016\/j.medcli.2025.106951_bib0510","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/biomedicines12102293","article-title":"Weight loss therapies and hypertension benefits","volume":"12","author":"Katsi","year":"2024","journal-title":"Biomedicines."},{"key":"10.1016\/j.medcli.2025.106951_bib0515","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0520","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0525","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0530","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2025.106951_bib0535","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0540","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: Current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.medcli.2025.106951_bib0545","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/HCO.0b013e32834b7fc4","article-title":"Reductions in cardiovascular risk after bariatric surgery","volume":"26","author":"Benraouane","year":"2011","journal-title":"Curr Opin Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0550","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0555","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2025.106951_bib0560","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106951_bib0565","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0570","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.106951_bib0575","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0580","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0585","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/eurheartj\/ehac121","article-title":"BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction","volume":"43","author":"Shah","year":"2022","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2025.106951_bib0590","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: Insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106951_bib0595","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000526808","article-title":"Clinical impact of glucagon-like peptide-1 receptor analogs on the complications of obesity","volume":"16","author":"Yazici","year":"2023","journal-title":"Obes Facts."},{"key":"10.1016\/j.medcli.2025.106951_bib0600","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:03:23Z","timestamp":1765461803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0025775325001770"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106951","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"F\u00e1rmacos con acci\u00f3n GLP-1 en el tratamiento de la obesidad: efectos sobre las variables cardiometab\u00f3licas y la enfermedad cardiovascular","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106951"}}